Cefixime for Alternative Syphilis Treatment
Public ClinicalTrials.gov record NCT03660488. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Clinical Trial Evaluating the Clinical Efficacy of Cefixime for Treatment of Early Syphilis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of the study is to evaluate the efficacy of oral cefixime as an alternative treatment for syphilis infection. One hundred adult patients (≥18 years old) with syphilis infection (positive Treponema Pallidum Particle Agglutination assay and RPR titer ≥ 1/8) will be recruited. Participants will be randomized (1:1) to receive either the standard of care Penicillin or Cefixime. During the study, participants will visit the clinic up to 5 times; at baseline visit, at 3, 6, 12 months after treatment initiation. Participants of the cefixime group will be required to visit the clinic 14 days after treatment initiation. In each visit, participants will be asked about current symptoms and do laboratory tests for syphilis (RPR). Subjects who have a 4-fold decrease (from study entry RPR) in RPR titers from baseline at 6 months will be considered a positive treatment response.
Study identification
- NCT ID
- NCT03660488
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 58 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 3, 2018 (Actual)
- Primary completion
- Jan 30, 2021 (Actual)
- Completion
- Jan 30, 2021 (Actual)
- Last update posted
- Jul 26, 2022
2018 – 2021
United States locations
- U.S. sites
- 10
- U.S. states
- 2
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| AHF Westside | Beverly Hills | California | 90211 | — |
| AHF Downtown Healthcare Center | Los Angeles | California | 90015 | — |
| AHF Carl Bean | Los Angeles | California | 90018 | — |
| AHF Hollywood Healthcare Center | Los Angeles | California | 90027 | — |
| AHF Wellness on Western Center | Los Angeles | California | 90027 | — |
| AHF Oakland Wellness Center | Oakland | California | 94606 | — |
| AHF Healthcare Center Oakland | Oakland | California | 94609 | — |
| AHF San Francisco | San Francisco | California | 94114 | — |
| AHF Valley | Sherman Oaks | California | 91403 | — |
| AHF Las Vegas Healthcare Center | Las Vegas | Nevada | 89109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03660488, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2022 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03660488 live on ClinicalTrials.gov.